Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS.

Lichtenberg FR.

Health Aff (Millwood). 2001 Sep-Oct;20(5):241-51.

2.

The effect of newer drugs on health spending: do they really increase the costs?

Civan A, Köksal B.

Health Econ. 2010 May;19(5):581-95. doi: 10.1002/hec.1494.

PMID:
19404925
3.

Do higher drug costs lead to better health?

Mintzes B, Lexchin J.

Can J Clin Pharmacol. 2005 Winter;12(1):e22-7. Epub 2005 Jan 7.

PMID:
16055941
4.

Economic costs of diabetes in the US in 2002.

Hogan P, Dall T, Nikolov P; American Diabetes Association..

Diabetes Care. 2003 Mar;26(3):917-32.

PMID:
12610059
5.

Health care for children and youth in the United States: annual report on patterns of coverage, utilization, quality, and expenditures by income.

Simpson L, Owens PL, Zodet MW, Chevarley FM, Dougherty D, Elixhauser A, McCormick MC.

Ambul Pediatr. 2005 Jan-Feb;5(1):6-44.

PMID:
15656707
6.

Effects of new drugs on overall health spending: Frank Lichtenberg responds.

Lichtenberg FR.

Health Aff (Millwood). 2007 May-Jun;26(3):887-90.

7.

Healthcare expenditures and patient satisfaction: cost and quality from the consumer's perspective in the US.

Fu AZ, Wang N.

Curr Med Res Opin. 2008 May;24(5):1385-94. doi: 10.1185/030079908X291994 . Epub 2008 Apr 2.

PMID:
18387219
8.

Prescription drugs and the changing concentration of health care expenditures.

Zuvekas SH, Cohen JW.

Health Aff (Millwood). 2007 Jan-Feb;26(1):249-57.

9.

The effect of tax subsidies on high health care expenditure burdens in the United States.

Selden TM.

Int J Health Care Finance Econ. 2008 Sep;8(3):209-23. doi: 10.1007/s10754-008-9043-1. Epub 2008 Jun 29.

PMID:
18587643
10.

Drug-related morbidity and mortality: an economic and clinical perspective.

Bootman JL.

Manag Care. 2002 Feb;11(2 Suppl):12-5. No abstract available.

11.

Spending on medicines in Israel in an international context.

Sax P.

Isr Med Assoc J. 2005 May;7(5):286-91.

12.

The utility of prediction models to oversample the long-term uninsured.

Cohen SB, Yu WW.

Med Care. 2009 Jan;47(1):80-7. doi: 10.1097/MLR.0b013e3181844e2e.

PMID:
19106735
14.

Out-of-pocket and total costs of fixed-dose combination antihypertensives and their components.

Rabbani A, Alexander GC.

Am J Hypertens. 2008 May;21(5):509-13. doi: 10.1038/ajh.2008.31. Epub 2008 Mar 20.

PMID:
18437141
15.

The utility of extended longitudinal profiles in predicting future health care expenditures.

Cohen SB, Ezzati-Rice T, Yu W.

Med Care. 2006 May;44(5 Suppl):I45-53.

PMID:
16625064
16.

The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy. A systematic review.

Connock M, Frew E, Evans BW, Bryan S, Cummins C, Fry-Smith A, Li Wan Po A, Sandercock J.

Health Technol Assess. 2006 Mar;10(7):iii, ix-118. Review.

17.

Direct costs of COPD in the U.S.: an analysis of Medical Expenditure Panel Survey (MEPS) data.

Miller JD, Foster T, Boulanger L, Chace M, Russell MW, Marton JP, Menzin J.

COPD. 2005 Sep;2(3):311-8.

PMID:
17146996
18.

Regression-based sampling for persons with high health expenditures: evaluating accuracy and yield with the 1997 MEPS.

Moeller JF, Cohen SB, Mathiowetz NA, Wun LM.

Med Care. 2003 Jul;41(7 Suppl):III44-III52.

PMID:
12865726
19.

Do newer prescription drugs pay for themselves? A reassessment of the evidence.

Zhang Y, Soumerai SB.

Health Aff (Millwood). 2007 May-Jun;26(3):880-6.

Supplemental Content

Support Center